Jeff Amacker, TibaRay - Cancer Radiation Treatment Therapy | LSI Europe '22

Transcription

Jeff Amacker  0:03  

Thank you, I'm delighted to have the opportunity to tell you about some breakthrough technology that's going to dramatically change the field of radiation oncology. So let's start with some numbers, one out of two, and one out of three. What are the significance of these numbers? One out of two men and one out of three women will get cancer in their lifetimes. Of those 60% in the developed world today would get radiation therapy. With the we're talking about large numbers of patients in a very big problem. And the problem is that radiation therapy today is too slow. It's too slow, because we just the technology of linear accelerators was developed 60 years ago, and we haven't had a breakthrough in that technology. And so we've gone as fast as we can in treating radiation therapy patients, but it's too slow. And too slow is a problem. Because first of all the tumor moves, you had a happy meal for breakfast or you breathe, things move around the tumor moves, so we treat large volumes of normal tissue and burn it while we're trying to treat the tumor. It also turns out that the radiobiology, if you are treating a tumor, and you do it over a long period of time, while that treatment is happening, your normal tissue is getting burned. If you can treat it much more quickly, the radiation does less damage to the normal tissue, even with the same amount of damage to the tumor. And it's a bottleneck, the number of patients who can treat on a machine is limited by the speed of treatment. So our solution curing cancer in a flash, we're gonna do radiotherapy in a fraction of a second, it's 400 times faster than the current several minute treatments times that it takes. And when you do that, take an image treat it's done, there isn't time for the tumor to move around the tumors basically frozen in place, we can shrink the amount of normal tissue that we have to treat. And we get to take advantage of the radiobiology benefit of a very fast treatment. And we'll be able to treat at least twice as many patients on one of our machines as can currently be treated. So it's a more efficient treatment and a better treatment. So how do we do this 400 times faster? Well, it came down to originally originally a breakthrough in linear accelerator design, this came out of the SLAC National Accelerator Laboratory will get 30 times more beam current out of one of our accelerators than anything that's used in radiotherapy today. And we're putting 16 accelerators in a ring and delivering all that radiation at the tumor all at once. From all of those different directions at 30 times more beam than we have today. There is no mechanical motion. And as you'll see in a minute, the current radiotherapy trimming, there's lots of mechanical motion in order to try to distribute the radiation the way we want it to sculpt the dose the way we want it, we can do all of that without having to move things. So here's an example. This is a 25 Gray lung flat lung cancer treatment. This is a Varian TrueBeam. Doing gated rapid art. This is the state of the art latest therapy on the top of the top of the line machine. And what happens to the linear accelerators actually laying in the bottom of the accelerator as you see it here. And you'll see that it rotates around and the radiation is delivered from all these different directions. And this treatment is going to take over three minutes to deliver. Instead, we're done. third of a second, same exquisitely sculpted dose distribution that you get with all this mechanical motion and we do it in a third of a second instead of three minutes. It's all the problems that we talked about about motion gone, better, better radiobiology and a more efficient treatment. The team we have across the middle are our founders, two of them came out of slack, accelerate world accelerator experts. Three of them came out of Radiation Oncology at Stanford healthcare. And they got together and said, Hey, we have a real problem and radiation therapy. And we have a technology that was developed at SLAC for other reasons, and put it together to come up with this. I joined I had 28 years at Varian medical systems, the market leader, I know how to do these kinds of projects, and I understand the radiotherapy business really well. A rune manages the whole engineering team, we have a part time CFO Carol she's great keeps us straight, and a great set of advisors who are helping us to go make this happen. In terms of IP, we have exclusive licenses to a package of 15 patents, both US and international out of Stanford. These are both very broad and more specific to what we need. So for example, the idea of using more than one accelerator to treat a radiotherapy patient at the same time is patented, and we have that patent we have we also have a bunch of temporary IP on top of this that we are continuing to develop all the staff of Stanford pass ends are issued patents, the others are pending. So now what does this mean competitively, we're going to disrupt the competitive landscape. So here's the two by two, we have treatment speed across the bottom, we have the conventional, slow, multi minute treatments on the left hand side, that's what's happening today. And then we have sub second type of treatments on the right hand side. And then cost effectiveness on the other axis. On the bottom of cost effectiveness are the proton vendors. So proton therapy vendors, and then there's the main bulk of radiation oncology on top of them, that's more cost effective. So in terms of treatment speed, all of the proton vendors are going to be able to do this very fast treatment, they're working on it, now they're going to figure out how to do it. They're actually running clinical trials on some of it. Now we'll get to piggyback on that. The problem with protons is those machines are gigantic, and it's super expensive. So we're talking about a gantry that weighs 200 tons, as opposed to what we're going to build as a thing that fits inside a 10 foot tall radiotherapy vault. The current the vendors in the mainstream part of the business, which is where we can really do this don't have the technology to get there. Varian, for example, who's the market leader is doing this in protons, they have a proton business, they're trying to do this in protons, I'm not worried about protons, they're too expensive. So for a fraction of the proton price, we're the only ones who are going to be able to do this subsecond radiotherapy in existing radiotherapy vaults, get the benefits for the patients and do that, in addition, we're gonna be able to do it with exquisite dose, dose sculpting. And the proton vendors are sacrificing that. So it's a unique tube array only solution that we're coming out with. So how are we gonna make money doing this? Heck, yeah, we're talking a market of 7 billion tam growing at 6% per year for the for the equipment, the whole industry of radiotherapy is a profitable industry. If we have to go the whole road, we're running the business to go the whole road. But if the whole road, we can still build a very nice business, we get to 5% share of new machines, five years after introduction, we're looking at a $1.6 billion valuation profitable type of business in five years. However, a strategic acquisition is more likely, the elite market leaders in this field can't be disrupted like this. So we'll see what happens. But there's so there's potential upside on this business model. It's a four year development project, have a project plan that says three years, that won't happen in three, it's a four year development effort to go make this happen. from a regulatory standpoint, we can go in with existing radiotherapy machines as a predicate device, and do a 510 K and put our machines into leading institutions, then any follow on work that we want to do on the piggyback on whatever happens with proton trials we can do at those institutions. And it's a separate it's a later regulatory pathway to make additional claims. So we can go to market with a straightforward regulatory pathway, CE mark is kind of in between. In terms of funding, we have currently have a convertible note open $4 million convertible note. And that's in advance of going to a series a as soon as we're done finished with the last of the technical derisking, we're going to open series A expect that in the next six months. So to recap, why Tibaray first of all, one out of two, one out of three, the need is huge. We're just we got disruptive technology, we're going to treat cancer patients in a fraction of a second 400 times faster. And by doing that, we're going to get better clinical outcomes. Because there isn't time for stuff to move around. We can treat smaller volumes and do less damage to normal tissue and take advantage of the radiobiology. And in a more efficient, efficient package where we can treat twice as many patients on a machine. We've got the expertise of the team to do it. So we're uniquely positioned to save millions of lives and we'll make money along the way. Thank you